{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:27:49Z","timestamp":1789954069365,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Japanese Ministry of Labor, Health and Welfare","award":["26380101"],"award-info":[{"award-number":["26380101"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.virusres.2015.11.010","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T16:46:06Z","timestamp":1447173966000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice"],"prefix":"10.1016","volume":"213","author":[{"given":"Takuro","family":"Uchida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Miyaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chise","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan D.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2015.11.010_bib0005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jmv.22158","article-title":"Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state","volume":"83","author":"Abe","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2015.11.010_bib0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nature04078","article-title":"Evasion of intracellular host defence by hepatitis C virus","volume":"436","author":"Gale","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.11.010_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2015.11.010_bib0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24460","article-title":"Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo","volume":"54","author":"Hiraga","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2015.11.010_bib0030","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jmb.2013.10.032","article-title":"Activation and evasion of antiviral innate immunity by hepatitis C virus","volume":"426","author":"Horner","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","article-title":"Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus","volume":"12","author":"Kiyosawa","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2015.11.010_bib0040","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/hep.21209","article-title":"Anti-HCV therapies in chimeric scid-Alb\/uPA mice parallel outcomes in human clinical application","volume":"43","author":"Kneteman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2015.11.010_bib0045","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2015.11.010_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2013.02.008","article-title":"A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1HCV infection who have failed previous pegylated interferon and ribavirin treatment","volume":"59","author":"Lawitz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1128\/AAC.00677-09","article-title":"MK-7009, a potent and selective inhibitor of hepatitis C virus NS3\/4A protease","volume":"54","author":"Liverton","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2015.11.010_bib0060","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-na\u00efve patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2015.11.010_bib0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.virusres.2015.11.010_bib0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virusres.2015.11.010_bib0075","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510280632","article-title":"Prognosis of chronic hepatitis C: results of a large, prospective cohort study","volume":"28","author":"Niederau","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2015.11.010_bib0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2010.08.033","article-title":"Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice","volume":"54","author":"Ohara","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0085","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/AAC.00990-10","article-title":"Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents","volume":"55","author":"Olsen","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2015.11.010_bib0090","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/gutjnl-2012-302600","article-title":"Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice","volume":"62","author":"Shi","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.virusres.2015.11.010_bib0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nrgastro.2013.165","article-title":"Viral hepatitis: treating hepatitis C in injection drug users","volume":"10","author":"Soriano","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jcv.2009.09.029","article-title":"Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir","volume":"47","author":"Suzuki","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0105","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","article-title":"Near completely humanized liver in mice shows human-type metabolic responses to drugs","volume":"165","author":"Tateno","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.virusres.2015.11.010_bib0110","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.20892","article-title":"Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus","volume":"42","author":"Tsuge","year":"2005","journal-title":"Hepatology"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170215301179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170215301179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:04:25Z","timestamp":1759154665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170215301179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":22,"alternative-id":["S0168170215301179"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2015.11.010","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2015.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}